InvestSMART

Clover Corporation Limited (ASX:CLV)

ALERT: Price-sensitive ASX Announcement for CLV
Current share price for CLV : $0.820 0.075 (10.07%)+
Announcement
Release
24 Mar 2026 8:19AM
Price at Release
$0.745
Full Release
download
Summary
Clover Corporation Limited announced a strong performance for the first half of FY26, with significant revenue growth to $44.1 million, driven by improved gross margins and EBITDA. The company's expansion into various human nutrition segments and strategic collaborations have bolstered its financial performance and market position. Clover declared an interim dividend and projected a positive revenue outlook for FY26. The company continues to focus on product innovation and geographical expansion, aiming for further growth in the second half of the financial year.
Key Points
  • Clover Corporation reported a strong performance for the first half of FY26 with revenue of $44.1 million, a significant increase from $37.6 million in 1H FY25.
  • The company's gross margin improved to 35.6%, an 850 basis point increase from the previous year.
  • Clover's EBITDA rose to $6.9 million, up from $4.3 million in the same period last year.
  • Net Profit After Tax (NPAT) increased to $4.2 million compared to $2.4 million in 1H FY25.
  • Clover's Board declared a fully franked interim dividend of 1.0 cent per share.
  • The company is actively expanding its product portfolio and market reach, particularly in human nutrition segments including seniors, toddlers, and adult nutrition.
  • Strategic investments and collaborations, such as with Melody Dairies and tuna oil extraction in Ecuador, are contributing to Clover's growth and diversification.
  • Clover is working on the registration and approval of its DHA emulsion, Premneo, across various global markets.
  • The revenue guidance for FY26 is projected between $92 and $96 million.
  • Clover continues to innovate with new products like CholineXcel® and diversified DHA formulations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.